SCHEMBL25816713

SCHEMBL25816713

CC(C)(C)OC(=O)N1OCC[C@H]1c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.46
RIPK1 Q13546 1/20 0.44
USP30 Q70CQ3 1/20 0.40
BCL2 P10415 1/20 0.39
BECN1 Q14457 1/20 0.39
HSD11B1 P28845 1/20 0.39
GRM5 P41594 2/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
POLB P06746 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
GRM1 Q13255 1/20 0.37
MMP13 P45452 1/20 0.37
NPEPPS P55786 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338718 1.00 GPR119 (0.46) GPR119RIPK1USP30BCL2BECN1
SCHEMBL30547544 0.83 GPR119 (0.46) GPR119USP30
SCHEMBL25816509 0.83 GPR119 (0.46) GPR119USP30
SCHEMBL30338607 0.81 MEN1 (0.37) POLBMEN1ALDH1A1LMNATSHR
SCHEMBL25816517 0.81 MEN1 (0.37) POLBMEN1ALDH1A1LMNATSHR
SCHEMBL24454703 0.81 RIPK1 (0.48) GPR119RIPK1
SCHEMBL22210854 0.81 RIPK1 (0.48) GPR119RIPK1
SCHEMBL18921510 0.81 RIPK1 (0.48) GPR119RIPK1
SCHEMBL22039535 0.80 HSD11B1 (0.54) GPR119RIPK1HSD11B1NPC1RAB9A
SCHEMBL29785710 0.80 HSD11B1 (0.54) GPR119RIPK1HSD11B1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 GPR119 420/4885RIPK1 1/4885USP30 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.